Andrew Currie is a basic scientist with experience in the fields of paediatric innate immunity and infectious disease, with a focus on neonatal sepsis. He currently leads the Neonatal Immunology Research Group in partnership with Neonatology Consultant, Dr Tobias Strunk. The group’s research combines current cellular and molecular ‘omics’ methodologies with primary human samples, and more recently large animal neonatal studies, to understand how the innate immune system contributes to defence against infection in early life. Andrew’s goal is to trial and translate key research findings into cost-effective and safe innate immune therapies for preventing and limiting infection and inflammation in preterm infants. The group is currently working on developing molecular diagnostic approaches for sepsis and trialing novel immunomodulatory antimicrobial agents as adjuncts for sepsis treatment.